Dose-response curves for agents that impair cell reproductive integrity. The relation between dose-response curves and the design of selective regimens in cancer chemotherapy.

Berenbaum, M. C.

doi:10.1038/bjc.1969.56

Cited by 21 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, individual survival curves of radiation and chemotherapeutic agents can be employed to characterize the survival curve for the combined case. Several clonogenic-assay studies suggest that survival curves of cell lines that are only exposed to chemotherapeutic agents have an exponential form in terms of the drug's concentration (see, e.g., Berenbaum (1969); Eichholtz-Wirth (1980); Giocanti et al (1993); Skipper et al (1964)). Hence, to account for the additivity mechanism, one may add a linear term with respect to the drug's concentration to the exponent of the LQ model (see Appendix A).…”

Section: Additivity Mechanismmentioning

confidence: 99%

A mathematical programming approach to the fractionation problem in chemoradiotherapy

Salari

Unkelbach

Bortfeld

2015

IIE Transactions on Healthcare Systems Engineering

View full text Add to dashboard Cite

In concurrent chemoradiotherapy, chemotherapeutic agents are administered during the course of radiotherapy to enhance the primary tumor control. However, that often comes at the expense of increased risk of normal-tissue complications. The additional biological damage is mainly attributed to two mechanisms of action, which are the independent cytotoxic activity of chemotherapeutic agents and their interactive cooperation with radiation. The goal of this study is to develop a mathematical framework to obtain drug and radiation administration schedules that maximize the therapeutic gain for concurrent chemoradiotherapy. In particular, we analyze the impact of incorporating these two mechanisms into the radiation fractionation problem. Considering each mechanism individually, we first derive closed-form expressions for the optimal radiation fractionation regimen and the corresponding drug administration schedule. We next study the case in which both mechanisms are simultaneously present and develop a dynamic programming framework to determine optimal treatment regimens. Results show that those chemotherapeutic agents that interact with radiation may change optimal radiation fractionation regimens. Moreover, administration of chemotherapeutic agents possessing both mechanisms may give rise to optimal non-stationary fractionation schemes.

show abstract

Section: Additivity Mechanismmentioning

confidence: 99%